The 7H22-E16 monoclonal antibody specifically binds to CD268, which is also known as, B cell-activating factor receptor (BAFF-R), or BAFF Receptor 3 (BR3). CD268 is a type III transmembrane protein that is likewise known as Tumor necrosis factor receptor superfamily member 13C (Tnfrsf13c). CD268/BAFF-R is a receptor for CD257 (also known as, BAFF, Blys, TALL-1, or THANK) and is expressed on B cells and a subset of activated/memory CD4+ T cells. B cells express two other BAFF receptors, CD267/TACI, or CD269/BCMA, at various times during their differentiation. CD268/BAFF-R expression starts at the transitional stage of B cell development and increases throughout B cell maturation. CD267/BAFF-R mediates most BAFF-dependent functions including B cell survival, the activation of B cell proliferation and immunoglobulin secretion, and the costimulation of T cells. Overexpression of BAFF in mice and humans is associated with autoimmunity, whereas CD268/BAFF-R deficiency may cause severe impairment in humoral responses.
The antibody was conjugated to BD Horizon BUV615 which is part of the BD Horizon Brilliant™ Ultraviolet family of dyes. This dye is a tandem fluorochrome with an Ex Max near 350 nm and an Em Max near 615 nm. BD Horizon Brilliant BUV615 can be excited by the ultraviolet laser (355 nm) and detected with a 610/20 filter and a 595 nm LP. Due to the excitation of the acceptor dye by the blue/yellow-green laser line, there may be significant spillover into channels detecting PE-CF594 like emissions (eg, 610/20-nm filter).